Clinical pharmacokinetics and pharmacodynamics of cholinesterase inhibitors

Clinical Pharmacokinetics

Volumn 41, Issue 10, 2002, Pages 719-739

  Jann, M W ^a   Shirley, K L ^a,b   Small, G W ^c  

^a MERCER UNIVERSITY   (United States)

^b ALBANY COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINESTERASE; CHOLINESTERASE; CHOLINESTERASE INHIBITOR; CIMETIDINE; CYTOCHROME P450; DIGOXIN; DONEPEZIL; FLUVOXAMINE; GALANTAMINE; HORMONE; KETOCONAZOLE; PSYCHOTROPIC AGENT; RIVASTIGMINE; TACRINE; THEOPHYLLINE; WARFARIN;

ALZHEIMER DISEASE; AREA UNDER THE CURVE; BEHAVIOR; DELUSION; DIARRHEA; DOSE RESPONSE; DRUG ABSORPTION; DRUG ANTAGONISM; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG STRUCTURE; ENZYME INHIBITION; FAINTNESS; HUMAN; LIVER TOXICITY; NAUSEA; PHARMACODYNAMICS; PRIORITY JOURNAL; RASH; RATING SCALE; RESTLESSNESS; REVIEW; SWEATING; TREMOR; VERTIGO; VOMITING;

EID: 0036349129     PISSN: 03125963     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003088-200241100-00003     Document Type: Review

References (100)

1. Molecular basis of the neurodegenerative disorders
2. Cognitive enhancement therapy for Alzheimer's disease
3. Recent developments in the drug treatment of Alzheimer's disease
4. Cholinesterase inhibitors for the treatment of Alzheimer's disease in the elderly
5. CNS nicotinic receptors
6. Oxidative injury in diseases of the central nervous system: Focus on Alzheimer's disease
7. Statins and the risk of dementia
8. Diagnosis and treatment of Alzheimer's disease and related disorders
9. Anticholinesterase agents
10. Pharmacodynamic tolerability relationships of cholinesterase inhibitors for Alzheimer's disease
11. Cholinesterase inhibitors: A new class of psychotropic compounds
12. Tacrine: First drug approved for Alzheimer's disease
13. Clinical pharmacokinetic of drugs for Alzheimer's disease
14. Pharmacokinetics of tacrine hydrochloride in Alzheimer's disease
15. Steady-state pharmacokinetics of tacrine in patients with Alzheimer's disease
16. Clinical pharmacokinetics of intravenous and oral 9-amino-1,2,3,4-tetrahydroactidine, tacrine
17. Clinical pharmacokinetics of tacrine
18. Cholinesterase inhibitors in the treatment of Alzheimer's disease
19. Tacrine: A review of its pharmacological and pharmacokinetic properties and therapeutic potential in Alzheimer's disease
20. Plasma protein binding characteristics of tacrine hydrochloride (THA)
21. Penetration of tacrine into cerebrospinal fluid in patients with Alzheimer's disease
22. Combined glutathione-S-transferase M1 and T1 genetic polymorphism and tacrine hepatotoxicity
23. Acetylcholinesterase inhibitors in Alzheimer's disease
24. Evaluation of HP-029 (velnacrine maleate) in Alzheimer's disease
25. Donepezil
26. Donepezil use in Alzheimer's disease
27. Pharmacokinetics and pharmacodynamic profile of donepezil HCL following single oral dose
28. Pharmacokinetics and pharmacodynamic profile of donepezil HCl following multiple oral dose
29. Donepezil improves cognition and global function in Alzheimer's disease
30. Donepezil: An anticholinesterase inhibitor for Alzheimer's disease
31. Metabolism and elimination of 14C donepezil in healthy volunteers: A single dose study
32. Comparison of the pharmacokinetics of E2020, a new compound for Alzheimer's disease, in healthy young and elderly subjects
33. An evaluation of the pharmacokinetics of donepezil hydrochloride in patients with impaired hepatic function
34. An evaluation of the pharmacokinetics of donepezil hydrochloride in patients with impaired moderate to severe renal impairment
35. Rivastigmine, a new generation cholinesterase inhibitor for the treatment of Alzheimer's disease
36. Safety/tolerability trial of SDZ 713 in patients with probable Alzheimer's disease
37. Rivastigmine
38. Preferential cerebrospinal fluid acetylcholinesterase inhibition by rivastigmine in humans
39. Dose-dependent CSF acetylcholinesterase inhibition by SDZ ENA 713 in Alzheimer's disease
40. The effects of renal and hepatic impairment on the disposition of acetylcholinesterase SDZ ENA 713
41. Galantamine
42. Pharmacokinetic of galantamine hydrobromide after single subcutaneous and oral dosage in humans
43. Pharmacokinetic studies of cholinesterase inhibitors
44. Pharmacokinetics of galantamine in humans and corresponding cholinesterase inhibition
45. Differential increase in CSF acetylcholinesterase after treatment with acetylcholinesterase inhibitors in patients with Alzheimer's disease
46. The O-demethylation of the antidementia drug galantamine is catalysed by cytochrome P450 2D6
47. Caffeine based measures of CYP 1A2 correlate with oral clearance of tacrine in patients with Alzheimer's disease
48. Serum concentrations of tacrine hydrochloride predict its adverse effects in Alzheimer's disease
49. The effect of smoking on the pharmacokinetics and metabolism of Cognex in healthy volunteers
50. Concurrent administration of donepezil HCl and digoxin: Assessment of pharmacokinetic changes
51. Inhibition of tacrine oral clearance by cimetidine
52. Plasma tacrine concentrations are significantly increased by concomitant hormone replacement therapy
53. Use of heterologously expressed human cytochrome P450 1A2 to predict tacrine-fluvoxamine drug interaction in man
54. Influence of the CYP 1A2 inhibitor fluvoxamine on tacrine pharmacokinetics in humans
55. Concurrent administration of donepezil HCl and cimetidine: Assessment of pharmacokinetic changes following single and multiple doses
56. Concurrent administration of donepezil HCl and ketoconazole: Assessment of pharmacokinetic changes following single and multiple doses
57. Donepezil and paroxetine: Possible drug interaction
58. Drug interactions with donepezil
59. Fulminant chemical hepatitis possibly associated with donepezil and sertraline therapy
60. The safety and pharmacokinetics of thioridazine during co-administration with donepezil
61. Pharmacokinetics of donepezil and risperidone in males with schizophrenia
62. Concurrent administration of donepezil HCl and theophylline: Assessment of pharmacokinetic changes following multiple doses in healthy volunteers
63. The effect of multiple doses of donepezil HCl on the pharmacokinetics and pharmacodynamics of warfarin
64. Lack of adverse pharmacodynamic drug interactions with rivastigmine and twenty two classes of medications
65. Preclinical pharmacology of metrifonate
66. The cholinesterases: From genes to proteins
67. Butyrylcholinesterase in the life cycle of amyloid plaques
68. Do cholinesterase inhibitors have disease-modifying effects in Alzheimer's disease?
69. Metrifonate: Overview of safety and efficacy
70. Allosteric sensitization of nicotinic receptors by galantamine, a new treatment for Alzheimer's disease
71. Maximum tolerated dose and pharmacodynamics of eptastigmine in elderly healthy volunteers
72. A 24-week double blind placebo controlled trial of donepezil in patients with Alzheimer's disease
73. Statistical issues in the design and analysis of clinical trials in Alzheimer's disease
74. A new rating scale for Alzheimer's disease
75. Validity and reliability of the Alzheimer's disease cooperative study: Clinical global impression of change
76. Cholinesterase inhibitors for Alzheimer's disease therapy: From tacrine to future applications
77. Mini-mental state exam
78. The neuropsychiatric inventory
79. Measurement of quality of life changes in patients with Alzheimer's disease
80. Cholinesterase inhibitors: A therapeutic strategy for Alzheimer's disease
81. Pharmacologic treatment of cognition in Alzheimer's dementia
82. A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease
83. A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer's disease
84. A 5-month randomized placebo controlled trial of galantamine in AD
85. Dose-response effect of rivastigmine in the treatment of Alzheimer's disease
86. Galantamine in AD: A 6-month randomized placebo controlled trial with a 6-month extension
87. Effect of tacrine on behavioral symptoms in Alzheimer's disease: An open label study
88. Effects of donepezil on emotional/behavioral symptoms in Alzheimer's disease patients
89. Cerebral pharmacodynamics of physostigmine in Alzheimer's disease investigated using SPECT
90. SPECT brain imaging in Alzheimer's disease during treatment with oral THA and lecithin
91. Patterns of brain activation in people at risk for Alzheimer's disease
92. Structural and functional imaging of Alzheimer's disease
93. A controlled trial of tacrine in Alzheimer's disease
94. The effect of donepezil in Alzheimer's disease: Results from a multinational trial
95. Efficacy and safety of rivastigmine in patients with Alzheimer's disease: International randomized controlled trial
96. Hepatotoxic effects of tacrine administration in patients with Alzheimer's disease
97. Glutathione S-transferase μ genotype (GSTM 1*0) in Alzheimer's patients with tacrine transaminitis
98. Practice guideline for the treatment of patients with Alzheimer's disease and other dementias of late life
99. Recognition and management of early Alzheimer's disease